|
|
|
|
|
|
By Life Science Connect Editorial Staff | While LNPs have emerged as the most promising non-viral delivery vehicles for mRNA therapeutics thus far, the field is rapidly expanding. To broaden mRNA’s applicability across a wider range of indications, companies are exploring innovative non-viral, non-LNP delivery vehicles, including polymers, engineered virus-like particles, and more. | |
|
|
|
In this Advancing RNA Live clip, panelists Stu Sundseth, Marc Wolfgang, and Christian Dohmen each provide their take on the most critical areas for improvement in mRNA process development. |
|
|
|
|
|
|
|
|
| Real-Time Monitoring Of Higher-Order Structure Of RNAs | Webinar | RedShiftBio | Learn how this biophysical characterization strategy can enhance RNA therapeutic candidate screening and formulation development through a deeper understanding of RNA structure under native conditions. |
|
|
|
|
|
|
|
| Webinar: Accelerate your pDNA and mRNA process development | Discover how to achieve high-yield plasmid DNA (pDNA) production in this Cytiva webinar. The Fast Trak™ team shares a systematic approach to developing and scaling a pDNA process using E. coli OneShot Top10. Learn how design of experiments (DOE), optimized culture conditions, and the Xcellerex™ XDR-50 fermentor enable seamless scale-up from benchtop to pilot scale while maintaining yield, quality, and process control. Click here to learn more. |
|
|
|
|
|
|
|
|
|
| Join us in a discussion around the role mRNA technology will play in the future of Canadian healthcare and how misinformation, polarization, and political partisanship is shaping its global future. The community is invited to an exclusive screening of The Messenger, a documentary showcasing the origin of mRNA technology, followed by a panel featuring mRNA pioneers and leading experts in public health and regulation. |
|
|
.png){kind=logo}
